Archives of Dermatological Research最新文献

{"title":"Systemic inflammation correlates with depression and lower quality of life in patients with hidradenitis suppurativa independent of disease severity","authors":"Nikolaos Rotsiamis,&nbsp;Natalia Rompoti,&nbsp;Aikaterini Liakou,&nbsp;Andreas G Tsantes,&nbsp;Stefanos Bonovas,&nbsp;George Samonis,&nbsp;Petros Ioannou,&nbsp;Alexandra Mpakosi,&nbsp;Ioannis-Alexios Koumprentziotis,&nbsp;Lydia Tsamtsouri,&nbsp;Eleni Chatzidimitriou,&nbsp;Soultana Vladeni,&nbsp;Stamatis Gregoriou,&nbsp;Electra Nicolaidou,&nbsp;Alexander Katoulis,&nbsp;Evangelia Papadavid,&nbsp;Dimitrios Rigopoulos","doi":"10.1007/s00403-025-04143-9","DOIUrl":"10.1007/s00403-025-04143-9","url":null,"abstract":"<div><p>Hidradenitis suppurativa (HS) is associated with a cumulative life course impairment and patients commonly present with signs of depression and anxiety. This study aimed to investigate the association between systemic inflammation, measured by laboratory markers, and psychological burden, evaluated using specific psychometric scores, in patients with HS. The study also evaluated the impact of treatment initiation on inflammatory biomarkers and psychometric scores. A prospective, observational, monocentric study was conducted on adult patients with HS of Hurley stage I, II and III, who were eligible for treatment initiation. Disease severity was assessed using the Hurley stage, and disease activity through the IHS4 scoring system. Laboratory evaluation of systemic inflammation included measurement of White Blood Cell count, Erythrocyte Sedimentation Rate (ESR) and C-reactive protein levels, at the study onset, right before treatment initiation, at 12 weeks and at 24 weeks following treatment onset. The impact of the disease on psychological status and overall quality of life was evaluated through psychometric scores. Our results indicate that systemic inflammation, reflected by laboratory inflammatory markers such as ESR, is associated with a higher probability of depression, loneliness and reduced quality of life independently of Hurley stage, severity score, and clinical characteristics such as gender and smoking status. Psychometric evaluation, including the presence of depression and loneliness in HS patients, independent of Hurley stage is advisable, especially in cases where serum inflammatory markers, such as ESR, are high.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143726743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Claudin-1 expression in acne and its correlation with disease severity: clinical and in silico validation","authors":"Haidy Sayed Rashad,&nbsp;Hesham A. Nada,&nbsp;Nader Ali Ismail,&nbsp;Noha M. Abd El-Fadeal,&nbsp;Nora Hosny,&nbsp;Mona A. Atwa","doi":"10.1007/s00403-025-04083-4","DOIUrl":"10.1007/s00403-025-04083-4","url":null,"abstract":"<div><p>The pilosebaceous unit is the site of a common chronic inflammatory skin disorder called acne. Tight junctions (TJ) are present in sebocytes and are primarily composed of claudin-1. When claudin-1 is knocked down, the TJ barrier leaks, and holocrine secretion is compromised. This leads to the accumulation of partially degenerated sebocytes in the pilosebaceous ducts and the creation of microcomedos, which can cause acne lesions. The study’s aim was to measure the claudin-1 gene and protein expression in acne patients’ blood samples and establish a correlation with the severity of the condition and their levels. 48 acne patients were involved and 48 matched control for age and sex. First samples were obtained from both groups and RNA was extracted from the whole blood sample followed by qPCR to measure the relative expression of the claudin-1 gene. Enzyme-linked immunosorbent assay (ELISA) was used to measure claudin-1 protein level. There were statistically significant lower relative expression of claudin-1 gene (p = 0.001) and its protein level (p = 0.001) in acne patients compared to controls (0.34 ± 0.32 vs 1.0 ± 0.0, 0.64 ± 0.62 vs 3.85 ± 2.14, respectively). There was a statistically significant inverse correlation between claudin-1 protein expression and acne severity (R = −0.374, p = 0.009). Computational and bioinformatics tools were used for enrichment analysis to better understand claudin-1 role in the context of the disease and provide possible therapeutic approaches. Claudin-1 dysregulation in acne patients, suggest that it have an impact on the severity and course of acne through affecting the epidermal barrier and facilitating inflammation.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment","authors":"Wenting Hu,&nbsp;Cheng Cao,&nbsp;Yujie Zheng,&nbsp;Jindi Lei,&nbsp;Keyi Yu,&nbsp;Anqi Sheng,&nbsp;Rong Jin,&nbsp;Ai-e Xu","doi":"10.1007/s00403-025-04151-9","DOIUrl":"10.1007/s00403-025-04151-9","url":null,"abstract":"<div><p>Oral Janus Kinase (JAK) inhibitors represent a significant advancement in the treatment of vitiligo; however, large-scale clinical data on their optimal treatment duration and efficacy remain limited. This study aimed to evaluate the efficacy and safety of the oral JAK inhibitor tofacitinib in patients with active vitiligo over a 3-month period. A retrospective analysis was conducted on patients diagnosed with active vitiligo between June 2023 and January 2024 who received oral tofacitinib for at least 3 months. Data were extracted from patient records. Vitiligo activity was assessed based on the Vitiligo Disease Activity (VIDA) score in combination with specific clinical manifestations, while treatment efficacy was evaluated based on the Vitiligo Area Severity Index (VASI). Safety data were reviewed retrospectively throughout the treatment period. A total of 137 patients were included in the study. The VIDA score improved from 2.75 ± 1.15 at baseline to 1.63 ± 0.66 at treatment discontinuation, with 59.1% (81/137) of patients achieving disease stabilization. The baseline VASI score was 3.79 (1.54-4.0), which decreased to 2.68 (1.0-2.92), reflecting an overall 29.3% improvement. After 3 months of treatment, 98 patients continued to take tofacitinib. Patients who received treatment for 6–9 months demonstrated significantly greater repigmentation (42.27% improvement) compared to those treated for less than 6 months (<i>P</i> &lt; 0.05). No significant differences in efficacy were observed between non-segmental and segmental vitiligo. Mild adverse reactions were reported in 13.8% of patients, primarily including gastrointestinal discomfort, acne, elevated liver enzymes, and palpitations, with no severe adverse events recorded. In conclusion, oral tofacitinib administered for 3 months effectively stabilized vitiligo progression, while treatment extending to 6–9 months results in greater repigmentation and maintained a favorable safety profile. Further long-term controlled studies are warranted to validate these findings and optimize treatment strategies.</p><p>\u0000 Trial registration: http://www.chictr.org.cn. identifier: ChiCTR2400092326.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04151-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143726693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis","authors":"Wenzhuo Jiang,&nbsp;Qiujv Li,&nbsp;Wenjun Zheng","doi":"10.1007/s00403-025-04174-2","DOIUrl":"10.1007/s00403-025-04174-2","url":null,"abstract":"<div><p>This study aims to compare the efficacy of IL-17 and IL-23 biologics in the treatment of plaque psoriasis (Psoriasis vulgaris) in patients with metabolic syndrome (MetS) and to explore the effects of different biologics on metabolic indicators, particularly regarding the differences in efficacy during long-term treatment. This is a randomized controlled clinical trial involving 120 moderates to severe plaque psoriasis patients, of which 60 have metabolic syndrome and 60 do not. The patients were randomly assigned to three groups: IL-17 biologics group, IL-23 biologics group, and cyclosporine control group. Treatment lasted for three months, with evaluation indicators including psoriatic lesion assessment (PASI score), blood glucose levels, lipid profile (triglycerides, HDL-C), inflammatory markers (CRP, ESR, IL-6), etc. Patients were assessed at baseline, after one month, and after three months of treatment for both clinical efficacy and changes in metabolic indicators. Both IL-17 and IL-23 biologics demonstrated superior efficacy compared to cyclosporine in treating plaque psoriasis. After one month and three months of treatment, PASI scores in the IL-17 and IL-23 groups were significantly lower than in the control group, and the therapeutic effects were more pronounced (<i>P</i> &lt; 0.05). The IL-17 and IL-23 groups also showed better improvements in blood glucose, blood lipids (TG and HDL-C), and inflammatory markers (CRP, ESR, IL-6) compared to the control group. After three months of treatment, fasting blood glucose, fasting insulin, triglycerides, and CRP levels were significantly lower in the IL-17 and IL-23 groups than in the control group (<i>P</i> &lt; 0.05). Metabolic syndrome had some impact on treatment outcomes, with the efficacy of IL-17 and IL-23 biologics being lower in patients with metabolic abnormalities compared to those without metabolic syndrome. However, the IL-23 biologic showed less impact from metabolic syndrome. IL-17 biologics had a rapid effect in the short term, while IL-23 biologics demonstrated superior efficacy in long-term treatment, particularly at the three-month mark, where both efficacy and metabolic improvements were better than the IL-17 group. Both IL-17 and IL-23 biologics are more effective than cyclosporine in treating plaque psoriasis and can improve metabolic indicators in patients. Although metabolic syndrome impacts the efficacy of IL-17 biologics, IL-23 biologics are less affected by metabolic syndrome and demonstrate better long-term efficacy. Therefore, IL-23 biologics are recommended for long-term treatment in plaque psoriasis patients with metabolic syndrome.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143716945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of cognitive functions in patients with rosacea: a case–control study","authors":"Dilek Menteşoğlu,&nbsp;Gökçe Işıl Kurmuş,&nbsp;Selda Pelin Kartal,&nbsp;Ayşe Gökçen Gündoğmuş","doi":"10.1007/s00403-025-04173-3","DOIUrl":"10.1007/s00403-025-04173-3","url":null,"abstract":"<div><p>Rosacea is a chronic inflammatory skin disease and the most prevalent cause of facial redness in adults. It is also associated with various systemic conditions. This study aimed to evaluate cognitive function in patients with rosacea and compare it to healthy controls. A total of 119 individuals, comprising 58 patients with rosacea and 61 controls, were enrolled between April 2023 and September 2024. The Trail Making Test (TMT) was administered to all the participants to assess their cognitive function. In rosacea patients, TMT Part A was 37.9 ± 4.38, and TMT Part B was 73.4 ± 13.28. In the control group, TMT Part A was 38.5 ± 4.86, and TMT Part B was 72.0 ± 9.34 (p = 0.57, p = 0.47, respectively). Based on rosacea severity, the patients were categorized as mild to moderate (n = 35) and severe to very severe (n = 23). There was no significant difference between these groups in TMT Part A and TMT Part B (p = 0.97, p = 0.24, respectively). In addition, according to the rosacea subtype, there was no difference between the groups in TMT Part A, TMT Part B, and years of education (p = 0.58, p = 0.89, and p = 0.20, respectively). Since rosacea may be associated with neurodegenerative diseases, such as Alzheimer’s disease, dementia, and Parkinson’s disease, TMT can be used to investigate cognitive functions.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143726649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Illness perception, psychological distress, and quality of life in patients with alopecia: a cross-sectional study from Riyadh, Saudi Arabia","authors":"Hend M. Alotaibi,&nbsp;Reem Bin Idris,&nbsp;Ahmed H. Alajlan,&nbsp;Abdulaziz A. Alghufaili,&nbsp;Maee Barakeh,&nbsp;Shaden A. Alobaid,&nbsp;Norah K. Algarzae","doi":"10.1007/s00403-025-04093-2","DOIUrl":"10.1007/s00403-025-04093-2","url":null,"abstract":"<div><h3>Background</h3><p>Alopecia, a condition marked by hair loss, includes androgenic alopecia (AGA), alopecia areata (AA), telogen effluvium (TE), and scarring alopecia, each with a unique pathophysiology that profoundly impacts psychological well-being, self-image, and quality of life (QoL), leading to anxiety and depression. Understanding illness perception and its connection to QoL and mental health in comorbid Saudi patients, especially in patients with the simultaneous presence of more than two medical conditions, remains limited. We aimed to assess Saudi patients’ perception of different types of alopecia and explore the relationship between illness perception, QoL, psychological factors, and comorbidities. Methods: A cross-sectional survey was conducted at King Khalid University Hospital, Riyadh, from December 2023 to March 2024. Ninety-nine adults with confirmed alopecia diagnoses completed validated questionnaires, including the Brief Illness Perception Questionnaire (BIPQ), the Dermatology Life Quality Index (DLQI), the Patient Depression Questionnaire (PHQ-9), and the Generalized Anxiety Disorder Scale (GAD-7). Statistical analysis included regression models to determine predictors of QoL impairment. Results: the most common type of alopecia was AGA (47.5%), followed by AA (30.3%), scarring alopecia (16.2%), and TE (6.1%). Median scores for BIPQ and DLQI were 49.0 and 6.0, respectively, indicating moderate illness perception and QoL impact. Anxiety and depression levels were generally mild, though scarring alopecia patients reported higher emotional distress. Negative illness perception was strongly associated with reduced QoL and higher anxiety and depression scores. Factors such as illness perception, anxiety, and mental health conditions were significant predictors of QoL impairment. Conclusion: Our findings underscore the psychological impact of alopecia and highlight the importance of addressing both physical symptoms and mental health in patient care. Thus, Targeted interventions focusing on illness perception and emotional well-being are crucial for improving outcomes.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143726692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of topical sildenafil formulations in enhancing wound healing outcomes: a narrative review","authors":"Maryam Shahrokhi,&nbsp;Fatemeh Naghibi,&nbsp;Sabah Moraghebi,&nbsp;Parmida Khorrami,&nbsp;Habibeh Mashayekhi-sardoo","doi":"10.1007/s00403-025-04152-8","DOIUrl":"10.1007/s00403-025-04152-8","url":null,"abstract":"<div><p>Sildenafil, a major phosphodiesterase type 5 (PDE5) inhibitor, is particularly known for treating erectile dysfunction. It has been suggested as a promising therapeutic medication for accelerating wound healing. This study aimed to summarize the efficacy of different formulations and dosages of sildenafil in enhancing wound healing, focusing on its formulations, dosages, and mechanisms of action. The study used relevant keywords to review studies involving animal models and human patients. No time limitation was considered in the current study. The outcomes measured included re-epithelization, vascularization, collagen formation, and overall healing efficacy. Topical sildenafil formulations indicated significant improvements in wound closure, vascularization, and collagen regeneration in skin wounds. A combination of platelet-rich plasma (PRP) and sildenafil increased skin wound healing. Different concentrations (topical 2% and 5% formulation, and 13 mg/kg orally) were useful, with specific dosages showing significant improvements in healing biomarkers. The underlying mechanisms of sildenafil for accelerating wound healing are increasing nitric oxide (NO) levels and collagen synthesis. Moreover, sildenafil triggers angiogenesis, and fibroblast migration and contributes to skin tissue repair and regeneration. Topical sildenafil can be a promising drug for increasing wound healing, with different formulations and dosages illustrating efficacy in improving healing outcomes. Since sildenafil is a cost-efficient, and readily available drug with few side effects, we suggest further research to optimize its use in clinical settings.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mendelian randomization in the discovery of risk factors for autoimmune skin diseases: a bibliometric and visualized analysis","authors":"Caiqin Mao,&nbsp;Lisheng Nan,&nbsp;Jianhua Bu,&nbsp;Xianwei Wu","doi":"10.1007/s00403-025-04171-5","DOIUrl":"10.1007/s00403-025-04171-5","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04171-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143706979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of the cosmetic use of botulinum toxin type a on temperature measurements using infrared thermography","authors":"José Eraldo Viana Ferreira,&nbsp;Maria Conceição Soares da Silva,&nbsp;Rafaela Pequeno Reis Sousa,&nbsp;Luiz Eduardo Marinho-Vieira,&nbsp;Diego Filipe Bezerra Silva,&nbsp;Jhonatan Thiago Lacerda-Santos,&nbsp;Daniela Pita de Melo","doi":"10.1007/s00403-025-04161-7","DOIUrl":"10.1007/s00403-025-04161-7","url":null,"abstract":"<div><p>This study aims to assess the influence of the cosmetic use of Botulinum toxin type A (BTX-A) on temperature measurements using Infrared thermography (IT). A quantitative cross-sectional study was conducted with 16 patients to examine the cosmetic application of BTX-A in the upper third of the face to treat dynamic wrinkles (expression lines). The substance used in the patients was Botulinum Toxin type A DYSPORT^® 500 IU. A thermogram in frontal norm was acquired from each patient in three different moments: (M1) before BTX-A application, (M2) 10 min after BTX-A application, and (M3) five days after BTX-A application. The ROIs were demarcated in each image with a diameter of 10 mm, and then the average temperature values of each ROI were recorded. Mixed ANOVA, with Tukey’s post hoc test, was used to determine interactions between factors in the dependent variable. The paired T-test was used to assess whether the mean temperatures on the face’s right and left sides were statistically different. The significance level was set at 5%, considering p &lt; 0.05. For the left-side temporal ROI, statistically significant differences were observed only between the different assessed times (p = 0.010). Considering the mean temperature difference, at the temporal ROI, a reduction of the M2 temperature was observed (ΔT = 0.3 ℃) and an increase at M3 (ΔT = 0.6 ℃). The cosmetic use of BTX-A may alter skin temperature values assessed using IT, and this effect can last for days.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04161-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of rosacea on neurodegenerative and neuropsychiatric diseases: a two-sample Mendelian randomization study","authors":"Xiangjun Hu,&nbsp;Dandan Shen,&nbsp;Hong Cai,&nbsp;Zhangren Yan","doi":"10.1007/s00403-025-04169-z","DOIUrl":"10.1007/s00403-025-04169-z","url":null,"abstract":"<div><p>This study aimed to explore the potential causal relationships between rosacea and Parkinson’s disease, Alzheimer’s disease, anxiety disorders, and depression with MR analysis. Genetic data for rosacea and the four neurodegenerative and neuropsychiatric disorders were sourced from GWAS databases. After completing stringent quality control procedures, SNPs meeting significance thresholds were selected as IVs. Our primary statistical analysis was conducted by IVW approach. To investigate the robustness of results, heterogeneity tests, sensitivity analyses, and pleiotropy assessments were conducted. Reverse MR analyses were subsequently carried out to further substantiate the causal relationships. The present study discovered a positive correlation between rosacea and an elevated risk of depression (OR = 1.0015, 95% CI = 1.0002–1.0027, <i>P</i> = 0.02). There is no causal evidence to support a connection between rosacea and Parkinson’s disease, Alzheimer’s disease, or anxiety disorders. Reverse MR analyses indicated no causal associations between these four disorders and the risk of rosacea. The findings reveal that individuals with rosacea may have an elevated risk of depression.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04169-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143716877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}